TELMICARD 5/40

Telmisartan USP 40 mg & Amlodipine USP 5 mg

Composition: Each film coated tablet comtains Telmisartan USP 40 mg & Amlodipine USP 5 mg

Pharmacology: Telmisartan is an orally effective and specific angiotensin-II receptor (type AT) antagonist. Absorption of telmisartan is rapid and the mean bioavailability is about 50%. When it is administered with food, the reduction in the area under the plasma concentration-time curve (AUC) of telmisartan varies approximately 6% (40mg). There is no linear relation between doses and plasma level. Telmisartan is largely bound to plasma protein (>99.5). Telmisartan is nearly exclusively excreted with faeces mainly as unchanged compound. Cumulative urinary excretion is 1% of dose. Amlodipine is a 1, 4 dihydropyridinr derivative Chalcium channel Blocker.

Indication: Telmisartan/Amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Dosage and Administration: Dosage must be individualized. The usual starting dose of telmisartan tablet is 40mg once a day. It may be used alone or in combination with other antihypertensive agent. Or, as directed by the registered physician.

Contraindicaion: It is contraindicated in patient who is hypersensitive to any component of the product.

Precautions: Telmisartan should be used with extreme caution in severe biliary obstructive disorder, severe hepatic impairment, progressive azotemia and severe renal impairment.

Side effects: Adverse events are generally mild and transient in nature. The events observed at the rate of 1% in association with the use of telmisartan including influenza like symptoms, dyspepsia, myalgia, urinary tract infection, abdomen pain, dizziness, nausea and peripheral edema. If the patient has any adverse reactions, he should report to this e-mail address: adrmcell.dgda@gmail.com.

Use in pregnancy and laction: When pregnancy is diagonised telmisartan should be discontinued as soon as possible because it directly acts on the rennin-angiotensin system during second and third trimester associated with fetal and neonatal injury. It is contraindicated during lactation since it is not known whether it is excreted in human milk.

Use In Child : No data found.

Drug Interactions : Telmisartan may increase the hypotensive effect of other antihypertensive agent. Serum lithium level monitoring is advisable during concomitant use of lithium with telmisartan. Other interaction of clinical significance has not been identified.

Overdose: Symptoms of overdose include: hypotension, dizziness, tachycardia, bradycardia.

Storage: Store below 30° C in a cool and dry place, Protect from light. Keep all medicines out of reach of children.

Packing : Each box contains 28 tablet in blister pack.

DRUG INTERNATIONAL LTD.
UNIT-3
31/1, SATRONG, TONGI I/A, GAZIPUR